Study Examines New Flu Vaccine for Older Adults
A recent study published in The Lancet investigated a new influenza vaccine for adults aged 65 and over. Researchers evaluated its effectiveness through a Phase 3 clinical trial. CSL Seqirus developed the vaccine, which integrates three established approaches to enhance protection.
Advertisement
MAIDENHEAD, United Kingdom – A new influenza vaccine for older adults has undergone review in a Phase 3 study, with findings published in The Lancet. CSL Seqirus, a CSL business, announced the publication on September 10, 2026.
The vaccine combines three methods designed to improve protection for individuals aged 65 and older. These approaches include a higher antigen dose, the use of an adjuvant, and a recombinant hemagglutinin (HA) protein.
Researchers conducted the study to assess the vaccine's ability to prevent influenza. They focused on adults in the 65 and over age group, a population segment known for experiencing more severe outcomes from influenza infections.
CSL Seqirus developed the vaccine. The company stated that the study provided data regarding its performance. This development represents an ongoing effort within the medical community to enhance influenza prevention strategies for vulnerable populations.
Related Topics
Article Ratings
How do you feel about this story?
National Desk
Sign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!